Practo and RBL Bank launch India’s first health-focused credit card

IMT News Desk
IMT News Desk
· 4 min read

The card offers benefits like unlimited online consultations, cashbacks in the form of HealthCash, free health checkups, to name a few

India, August 08, 2019: RBL Bank, one of India’s fastest growing private sector banks and Practo, India’s leading digital healthcare platform, have partnered to launch a co-branded credit card, powered by Mastercard. This industry-first credit card is available starting today, on both Practo and RBL mobile apps and websites. 

In a world where people are increasingly busy to pay attention to their day-to-day health needs, this is an innovative step to encourage users to think health-first on a daily basis. The card is designed to cater to customers in both metros and non-metro cities, through Practo and RBL Bank’s extensive customer base that spans across the country. With benefits like unlimited online consultations with doctors 24*7, users are guaranteed that there is an experienced qualified doctor available to them whenever there is a need – instead of relying on self-diagnosis or advice from friends and relatives. 

The benefits of RBL Bank Practo Plus credit card include:

  •  Unlimited online consultations with doctors 24*7 for 1 year
  •  One free full body health check-up 
  •  For every Rs. 100 spent on this card, cardholder earns 1 Practo HealthCash 
    • HealthCash can be used while availing Practo services like ordering medicine, tests, online consultations (1 Healthcash = 1 Rupee)

The moment the credit card is issued, a Practo health plan account gets created on Practo app. The cardholders need to login with their registered mobile number to access this plan under the “MyHealth Plan” section on Practo. The card also offers two complimentary domestic airport lounge access every quarter.

At the launch of the card, Harjeet Toor, Head – Retail, Inclusion & Rural Businesses, RBL Bank, said,We are delighted to enter into a partnership with Practo and launch a card that prioritizes good health and well-being. The partnership is a perfect example of how two diverse industries can come together to offer a compelling value proposition for customers. Healthcare is a largely untapped segment and this partnership will be a great opportunity for the Bank and Practo to leverage on each other’s strength to capture the market and offer customers a one-of-a-kind health card with exciting offers. The Bank’s credit cards business has performed extremely well this year and with this partnership we look forward to strengthen our business further by entering a new market segment.”

Commenting on the partnership, Tarun Bhambra, VP & Business Head, Practo, said: “We are delighted to partner with RBL Bank for launching a new credit card that is focused on making healthcare more affordable for consumers. We all have regular spends on appointments, medicine and diagnostic tests. This card gives a unique ability to consumers to use their regular spends for household expenses for subsidizing their monthly health spends on Practo platform. At Practo, it’s our constant endeavor to make healthcare simpler, more accessible and affordable. This card is one step towards achieving this vision.”

Digital healthcare market is on a tremendous uptake in India and is expected to reach $372 bn by 2022. Practo is currently the only platform in the country that lets patients manage their healthcare needs end-to-end. It provides a single platform that helps patients meet all their healthcare requirements at one go – from finding the right doctor to booking an appointment, online doctor consultation, getting lab tests done and medicines delivered. The company also enables doctors to digitise their medical practice management – lowering practice management burdens and increasing efficiency – extend their reach and visibility to patients, and even establish credibility through a digital presence complete with details of practice history, qualifications and documented patient experiences.  

To enrol for the card, please visit https://www.practo.com/plus/cards/rbl

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk